Effect of androgens combined with hormone therapy on quality of life in post-menopausal women with sexual dysfunction

Gynecological Endocrinology

Volumn 24, Issue 12, 2008, Pages 691-695

  Blumel, J E ^a   Del Pino, M ^b   Aprikian, D ^a   Vallejo, S ^a   Sarra, S ^a   Castelo Branco, C ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

androgen replacement therapy; hormone replacement therapy; Menopause; sexuality

Indexed keywords

CONJUGATED ESTROGEN; METHYLTESTOSTERONE; PLACEBO; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FOLLOW UP; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; MASTALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUALITY; SYMPTOMATOLOGY; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PSYCHOSEXUAL DISORDER;

DOUBLE-BLIND METHOD; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; METHYLTESTOSTERONE; MIDDLE AGED; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; STATISTICS, NONPARAMETRIC;

EID: 64349121310     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802454919     Document Type: Article

References (36)

1. Blumel JE, Castelo-Branco C, Binfa L, Gramegna G, Tacla X, Aracena B, Cumsille MA, Sanjuan AL. Quality of life after the menopause: a population study. Maturitas 2000;34:17-23.
2. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997;22:189-212.
3. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-236.
4. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-96.
5. Bell RJ, Donath S, Davison SL, Davis SR. Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause 2006;13:65-71.
6. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'agostino R. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191-208.
7. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
8. Brett KM, Chong Y. Hormone Replacement Therapy: Knowledge and Use in the States Unites. Hyattsville, Maryland: National Center for Health Statistics; 2001.
9. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1-20.
10. Blumel JE, Binfa L, Caltaldo L, Carrasco A, Izaguirre H, Sarra S. Indice de funcio'n sexual femenina: un test para evaluar la sexualidad de la mujer. Rev Chil Obstet Ginecol 2004;69:118-125.
11. Blumel JE, Castelo-Branco C, Binfa L, Gramegna G, Tacla X, Aracena B, Cumsille MA, Sanjuan A. Quality of life after the menopause: a population study. Maturitas 2000;34:17-23.
12. Word Medical Association. Declaration of Helsinki. JAMA 1997;277:925-926.
13. Castelo-Branco C, Blumel JE, Araya H, Riquelme R, Castro G, Haya J,GramegnaG.Prevalenceof sexualdysfunctionina cohort of middle-aged women: influences of menopause and hormone replacement therapy. J Obstet Gynaecol 2003;23:426-430.
14. Studd J. A comparison of 19th century and current attitudes to female sexuality. Gynecol Endocrinol 2007;23:673-681.
15. Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Women with low libido: correlation of decreased androgen levels with female sexual function index. Int J Impot Res 2005;17:148-153.
16. Gracia CR, Freeman EW, Sammel MD, Lin H, Mogul M. Hormones and sexuality during transition to menopause. Obstet Gynecol 2007;109:831-840.
17. Carney A, Bancroft J, Mathews A. Combination of hormonal and psychological treatment for female sexual unresponsiveness: a comparative study. Br J Psychiatry 1978;133:339-346.
18. Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. J Sex Med 2007; 4 (4 Part 1): 1001-1008.
19. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2006;13:770-779.
20. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 2006;13:387-396.
21. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165:1582-1589.
22. Phillips EH, Ryan S, Ferrari R, Green C. Estratest and estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance data, January 1989 to August 2002. Clin Ther 2003;25:3027-3043.
23. Simon J, Klaiber E, Wiita B, Bowen A, Yang HM. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women. Menopause 1999;6:138-134.
24. Adamson DL, Webb CM, Collins P. Esterified estrogens combined with methyltestosterone improve emotional wellbeing in postmenopausal women with chest pain and normal coronary angiograms. Menopause 2001;8:233-238.
25. Dias RS, Kerr-Correa F, Moreno RA, Trinca LA, Pontes A, Halbe HW, et al. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause 2006;13:202-211.
26. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev 2005;4:CD004509.
27. de Paula FJ, Soares JM Jr. Haidar MA, de Lima GR, Baracat EC. The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 2007;56:69-77.
28. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341-1352.
29. Sarrel P, Dobay B, Wiita B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. Sexual behavior and neuroendocrine responses. J Reprod Med 1998;43:847-856.
30. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-1020.
31. Zang H, Sahlin L, Masironi B, Eriksson E, Linde'n Hirschberg A. Effects of testosterone treatment on endometrial proliferation in postmenopausal women. J Clin Endocrinol Metab 2007;92:2169-2175.
32. Braunstein GD. Safety of testosterone treatment in postmenopausal women. Fertil Steril 2007;88:1-17.
33. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf) 2002;57:209- 214.
34. Gitlin N, Korner P, Yang HM. Liver function in postmenopausal women on estrogen-androgen hormone replacement therapy: a meta-analysis of eight clinical trials. Menopause 1999;6:216-224.
35. Female sexual dissatisfaction: hormone therapy inappropriate. Prescrire Int 2007;16:202-205.
36. Price P. Education, psychology and 'compliance'. Diabetes Metab Res Rev 2008; 24(Suppl 1): S101-S105.